Cancer targeted gene therapy of BikDD inhibits orthotopic lung cancer growth and improves long-term survival

Oncogene

Volumn 28, Issue 37, 2009, Pages 3286-3295

  Sher, Y P ^a   Tzeng, T F ^a   Kan, S F ^a   Hsu, J ^b   Xie, X ^b   Han, Z ^b   Lin, W C ^c   Li, L Y ^a,d   Hung, M C ^a,b,d  

^a CHINA MEDICAL UNIVERSITY   (Taiwan)

^b UNIVERSITY OF TEXAS   (United States)

^c CHINA MEDICAL UNIVERSITY   (Taiwan)

^d ASIA UNIVERSITY   (Taiwan)

Author keywords

BiKDD; Lung cancer; Survivin; Targeted gene therapy; VISA

Indexed keywords

BCL 2 INTERACTING KILLER PROTEIN; MUTANT PROTEIN; PROTEIN BCL 2; SURVIVIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CANCER GENE THERAPY; CANCER INHIBITION; CANCER SURVIVAL; CANCER TISSUE; CELL KILLING; CONTROLLED STUDY; CYTOMEGALOVIRUS; DRUG CYTOTOXICITY; EXPRESSION VECTOR; GENE EXPRESSION; GENE TARGETING; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; LUNG CANCER; MALE; MOUSE; NONHUMAN; PLASMID; PRIORITY JOURNAL; PROMOTER REGION; SURVIVAL TIME; TRANSGENE;

ANIMALS; APOPTOSIS REGULATORY PROTEINS; CELL LINE, TUMOR; CELL PROLIFERATION; CLINICAL TRIALS AS TOPIC; CYTOMEGALOVIRUS; GENE THERAPY; HUMANS; LUNG NEOPLASMS; MALE; MEMBRANE PROTEINS; MICE; MICROTUBULE-ASSOCIATED PROTEINS; MUTANT PROTEINS; NEOPLASM TRANSPLANTATION; NUCLEIC ACID AMPLIFICATION TECHNIQUES; PROMOTER REGIONS, GENETIC; SURVIVAL RATE; TIME FACTORS;

CYTOMEGALOVIRUS;

EID: 70349299843     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2009.187     Document Type: Article

References (25)

1. Altieri DC. (2003a). Survivin, versatile modulation of cell division and apoptosis in cancer. Oncogene 22: 8581-8589.
2. Altieri DC. (2003b). Validating survivin as a cancer therapeutic target. Nat Rev Cancer 3: 46-54.
3. Ambrosini G, Adida C, Altieri DC. (1997). A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 3: 917-921.
4. Chen JS, Liu JC, Shen L, Rau KM, Kuo HP, Li YM et al. (2004). Cancer-specific activation of the survivin promoter and its potential use in gene therapy. Cancer Gene Ther 11: 740-747.
5. Day CP, Rau KM, Qiu L, Liu CW, Kuo HP, Xie X et al. (2006). Mutant Bik expression mediated by the enhanced minimal topoisomerase II alpha promoter selectively suppressed breast tumors in an animal model. Cancer Gene Ther 13: 706-719.
6. Fitzsimons HL, Bland RJ, During MJ. (2002). Promoters and regulatory elements that improve adeno-associated virus transgene expression in the brain. Methods 28: 227-236.
7. Fukazawa T, Maeda Y, Durbin ML, Nakai T, Matsuoka J, Tanaka H et al. (2007). Pulmonary adenocarcinoma-targeted gene therapy by a cancer-and tissue-specific promoter system. Mol Cancer Ther 6: 244-252.
8. Gunther M, Wagner E, Ogris M. (2005). Specific targets in tumor tissue for the delivery of therapeutic genes. Curr Med Chem Anticancer Agents 5: 157-171.
9. Hay RJ, Reid YA, McClintock PR, Chen TR, Macy ML. (1996). Cell line banks and their role in cancer research. J Cell Biochem Suppl 24: 107-130.
10. Hoffman WH, Biade S, Zilfou JT, Chen J, Murphy M. (2002). Transcriptional repression of the anti-apoptotic survivin gene by wild type p53. J Biol Chem 277: 3247-3257.
11. Huang L, Hung M-C, Wagner E. (2005). Non-Viral Vectors for Gene Therapy, 2nd edn Part I & Part II. Elsevier Academic Press: San Diego, CA, USA.
12. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T et al. (2008). Cancer statistics, 2008. CA Cancer J Clin 58: 71-96.
13. Li F, Ling X. (2006). Survivin study: an update of 'what is the next wave'? J Cell Physiol 208: 476-486.
14. Li YM, Wen Y, Zhou BP, Kuo HP, Ding Q, Hung MC. (2003).Enhancement of Bik antitumor effect by Bik mutants. Cancer Res 63: 7630-7633.
15. McLemore TL, Eggleston JC, Shoemaker RH, Abbott BJ, Bohlman ME, Liu MC et al. (1988). Comparison of intrapulmonary, percutaneous intrathoracic, and subcutaneous models for the propagation of human pulmonary and nonpulmonary cancer cell lines in athymic nude mice. Cancer Res 48: 2880-2886.
16. Nigg EA. (2001). Mitotic kinases as regulators of cell division and its checkpoints. Nat Rev Mol Cell Biol 2: 21-32.
17. O'Connor DS, Schechner JS, Adida C, Mesri M, Rothermel AL, Li F et al. (2000). Control of apoptosis during angiogenesis by survivin expression in endothelial cells. Am J Pathol 156: 393-398.
18. Oshikiri T, Miyamoto M, Hiraoka K, Shichinohe T, Kawarada Y, Kato K et al. (2006). Transcriptional targeting of adenovirus vectors with the squamous cell carcinoma-specific antigen-2 promoter for selective apoptosis induction in lung cancer. Cancer Gene Ther 13: 856-863.
19. Ramirez RD, Sheridan S, Girard L, Sato M, Kim Y, Pollack J et al. (2004). Immortalization of human bronchial epithelial cells in the absence of viral oncoproteins. Cancer Res 64: 9027-9034.
20. Retzer-Lidl M, Schmid RM, Schneider G. (2007). Inhibition of CDK4 impairs proliferation of pancreatic cancer cells and sensitizes towards TRAIL-induced apoptosis via downregulation of survivin. Int J Cancer 121: 66-75.
21. Russ V, Wagner E. (2007). Cell and tissue targeting of nucleic acids for cancer gene therapy. Pharm Res 24: 1047-1057.
22. Templeton NS, Lasic DD, Frederik PM, Strey HH, Roberts DD, Pavlakis GN. (1997). Improved DNA: liposome complexes for increased systemic delivery and gene expression. Nat Biotechnol 15: 647-652.
23. Tsai MF, Wang CC, Chang GC, Chen CY, Chen HY, Cheng CL et al. (2006). A new tumor suppressor DnaJ-like heat shock protein, HLJ1, and survival of patients with non-small-cell lung carcinoma. J Natl Cancer Inst 98: 825-838.
24. Xie X, Xia W, Li Z, Kuo HP, Liu Y, Ding Q et al. (2007). Targeted expression of BikDD eradicates pancreatic tumors in noninvasive imaging models. Cancer Cell 12: 52-65.
25. Zaffaroni N, Pennati M, Daidone MG. (2005). Survivin as a target for new anticancer interventions. J Cell Mol Med 9: 360-372.